We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
GSK has suffered a sizeable blow after losing an appeal disputing that it had engaged in anti-competitive pay-to-delay tactics to block generic versions of its blockbuster antidepressant Seroxat from reaching the market.